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Although offering many benefits for several psychiatric disorders, antipsychotic drugs
(APDs) as a class have a major liability in their tendency to promote adiposity, obesity,
and metabolic dysregulation in an already metabolically vulnerable population. The past
decade has witnessed substantial research aimed at investigating the mechanisms of
these adverse effects and mitigating them. On July 11 and 12, 2011, with support from
2 NIH institutes, leading experts convened to discuss current research findings and to
consider future research strategies. Five areas where significant advances are being made
emerged from the conference: (1) methodological issues in the study of APD effects; (2)
unique characteristics and needs of pediatric patients; (3) genetic components underlying
susceptibility to APD-induced metabolic effects; (4) APD effects on weight gain and adipos-
ity in relation to their acute effects on glucose regulation and diabetes risk; and (5) the utility
of behavioral, dietary, and pharmacological interventions in mitigating APD-induced meta-
bolic side effects. This paper summarizes the major conclusions and important supporting
data from the meeting.
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INTRODUCTION
It is clear that weight gain is a ubiquitous side effect of antipsy-
chotic drugs (APDs; Allison et al., 1999) and that APDs are
also associated with an increased risk of complications related
to obesity, including insulin resistance, hyperlipidemia, type 2
diabetes mellitus, and cardiovascular disease (Lieberman et al.,
2005; Newcomer, 2005; Daumit et al., 2008; De Hert et al., 2011a).
However, the specific expression of APD-induced metabolic side
effects varies widely across APDs and across individuals. Although
patients with mental disorders in general have increased morbid-
ity and mortality, it is unclear how APDs specifically affect both
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psychiatric illness and also metabolic function in order to yield the
observed clinical outcomes.
It is widely accepted that most of the APDs induce significant
weight gain, with median weight changes of+0.2,−0.1,+0.7, and
+0.3 kg/month are observed for haloperidol, ziprasidone (ZIP),
olanzapine (OLZ), and risperidone (RISP), respectively, following
1 year of treatment (Parsons et al., 2009). Studies conducted within
a first-episode schizophrenia sample, such as in the Comparison
of Atypicals for First-Episode Psychosis (CAFÉ) study (McEvoy
et al., 2007) or the European First-Episode Schizophrenia Trial
(EUFEST) study (Kahn et al., 2008), and in antipsychotic-naïve
youth (Correll et al., 2009) have shown that all antipsychotics
are associated with varying degrees of significant weight gain
(Table 1). Moreover, when switching from an antipsychotic with a
higher weight gain risk to one with a lower risk,patients tend to lose
weight (Newcomer et al., 2008). Results of the Clinical Antipsy-
chotic Trials of Intervention Effectiveness (CATIE) study suggest
that female patients may be at a higher risk for weight gain; in fact
36.6% of male and 54.2% of female patients (and an overall rate of
42.7%) met the metabolic syndrome criteria (McEvoy et al., 2005).
However, findings on predictors of APD related weight gain have
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Table 1 | Mean (95% CI) antipsychotic-induced weight gain in pediatric and adult patients (kg).
Aripiprazole Risperidone Quetiapine Olanzapine
PEDIATRIC (Age <18 years) META-ANALYSIS
De Hert et al. (2011b) (N =3,048) 0.79 (0.54–1.04) 1.76 (1.27–2.25) 1.43 (1.17–1.69) 3.45 (2.93–3.97)
PEDIATRIC FIRST-EPISODEANDTREATMENT NAl¨VE STUDIES
Sikich et al. (2008) (N =116, ages 8–19, 8 weeks) N/A 3.6 (2.4–4.9) N/A 6.1 (4.9–7.4)
Correll et al. (2009) (N =272, ages 4–19, 12 weeks, 100% treatment naïve) 4.4 (3.7–5.2) 5.3 (4.8–5.9) 6.1 (4.9–7.2) 8.5 (7.4–9.7)
ADULT META-ANALYSES
Allison et al. (1999) (81 studies, 10, 6 weeks for quetiapine) N/A 2.10 (1.69–2.51) 2.18 (1.53–2.83) 4.15 (3.82–4.48)
Parsons et al. (2009) (10 studies, 4–12 weeks) N/A 1.95 (1.18–2.77) N/A 5.03 (4.08–5.94)
ADULT FIRST-EPISODEANDTREATMENT NAl¨VE STUDIES
Patel et al. (2009) (N =400, ages 16–40, 12 weeks) N/A 3.9 (3.85–3.95) 3.6 (3.55–3.65) 7.1 (7.05–7.15)
Perez-Iglesias et al. (2007) (N =128, 12 weeks, ages 15–48, 100% treat-
ment naïve)
N/A 5.6 (4.82–6.38) N/A 7.5 (6.61–8.39)
been mixed and seem to be influenced by prior treatment effects
(Correll et al., 2011).
The outcomes of a 2005 meeting underscored the significant
contribution of APDs to obesity-related conditions in psychiatric
patients and the need for further research on weight-management
programs tailored to this patient population (Allison et al., 2009b).
Since then, significant research efforts have focused on APD-
induced weight gain and related metabolic consequences. In July
of 2011, a follow-up conference to examine the current state of
the field was funded by the National Institute of Mental Health,
with additional funds from the National Institute of Diabetes
and Digestive and Kidney Diseases. The conference consisted of
expert presentations addressing topics ranging from clinical find-
ings to molecular mechanisms of APD-induced weight gain. The
discussion below reflects a distillation of the conference proceed-
ings, highlighting progress, key pharmacoepidemiological obser-
vations, and future needs in five key research areas. These areas
include: (1) methodological issues in the study of APD effects; (2)
unique characteristics and needs of pediatric patients; (3) genetic
and life-style risk factors underlying susceptibility to APD-induced
metabolic effects; (4) APD effects on weight gain and adiposity in
relation to their acute effects on glucose regulation and diabetes
risk; and (5) the utility of behavioral, dietary, and pharmaco-
logical interventions in mitigating APD-induced metabolic side
effects.
METHODOLOGICAL ISSUES IN THE STUDY OF APD EFFECTS
Two major categories of methodological issues were identified
during the conference: first, statistical challenges, and second, the
detection and proper reporting of adverse effects of APDs. In the
category of statistical issues, two in particular were highlighted:
1. Dealing with missing data; and, 2. analysis of heterogeneity in
response.
Missing data often arise when patients drop out of a study,
discontinue antipsychotic treatment, or switch to a different
antipsychotic drug, which produces a sample that is no longer
a population in which treatment assignment is guaranteed to be
independent of all pre-assignment covariates. This is a particu-
lar challenge for studies of antipsychotic drug metabolic effects,
because treatment discontinuation and switches are common,
often take place relatively soon after treatment initiation, and do
not occur randomly, being likely to be associated with clinical char-
acteristics that may in turn be associated with treatment outcomes
(informative censoring) in ways that may not be fully adjusted
for by available covariates. Most commonly, the last observation
carried forward (LOCF) technique is implemented; however, this
method is not likely to capture what would have occurred if the
patients who dropped out had remained in the study. Alternatively,
several mixed models and multiple imputation can be used to test
treatment effects (Elobeid et al., 2009), although caution is war-
ranted when using mixed models approaches with small sample
sizes and a large number of measurements, because Type 1 error
rates can become inflated (Ahn et al., 2000). Of course, it must be
kept in mind that the use of mixed models or multiple imputation
to conduct intention to treat (ITT) analyses, allows one to obtain
unbiased estimates of treatment assignment only under certain
assumptions, the critical one being that the data are missing at
random (MAR), meaning that the missing data are MAR condi-
tional on other variables in the model. This is a less restrictive
assumption than missing completely at random (MCAR) which is
required for analysis of completers only to be valid, but not an eas-
ily testable assumption (Little, 1988). Moreover, these methods test
the effect of treatment assignment, not treatment per se, and there
is no easy way nor universally accepted procedure that solves this
problem at the analytic level. Only designs which ensure perfect
conformity of treatment to treatment assignment and eliminate
drop-outs entirely can unequivocally solve such problems (Little
and Rubin, 2002). Empirical data can be used to inform expected
dropout rates for weight loss trial design (Elobeid et al., 2009), to
ensure a large enough sample size for adequate power. Addition-
ally, it should be noted that the type of analysis used affects power,
and that mixed models and multiple imputation have comparable
power, and are preferred to LOCF methods (Elobeid et al., 2009).
A second statistical and methodological challenge is the analy-
sis of heterogeneity in response to a given treatment, such as
inter-individual variation in APD-induced weight gain, and in
analyzing the contribution of genetic factors to this heterogeneity.
It is clear that genetic contributions to inter-individual variabil-
ity in treatment response can be profound (Bronikowski et al.,
2006). However, detecting treatment response heterogeneity in
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randomized controlled trials requires a specific study design,
because variation in outcome within the treatment group does not
necessarily indicate treatment response heterogeneity. Conceptu-
ally, true treatment response for an individual is the difference
between the change in the outcome variable after a pre-determined
treatment period and the change in the outcome variable during
the same time period had treatment not occurred (Gadbury et al.,
2001). This difference can be discussed theoretically, but cannot be
observed in reality. Commonly, studies seek to account for hetero-
geneity in weight gain response to APD treatment by correlating
with baseline BMI or other baseline covariates. Such analyses may
suffer from flaws, however, because any correlation may be a result
of regression to the mean, such that obese persons gain relatively
less weight and thin persons gain relatively more weight after an
obesogenic treatment (Allison et al., 2009a).
Several alternative methods can be used to identify treatment
response heterogeneity and covariates that may predict response.
Instead of a parallel group design, which can detect only a treat-
ment effect, a repeated-period crossover design in which each
patient receives both treatments at least twice is useful for detection
of treatment-patient interactions and treatment response hetero-
geneity (Senn, 2001). In addition, a simple method to calculate the
upper and lower bounds of treatment response heterogeneity in a
parallel groups has been proposed by Gadbury et al. (2001). Lastly,
Whole Genome Prediction can be used to predict which individ-
uals may respond better or worse to a particular treatment (de los
Campos et al., 2010), and although the method does not neces-
sarily explain why or which genes may be involved, it is a strong
prediction tool that uses all genetic markers available instead of
just a few.
Finally, there are methodological challenges in detecting
adverse effects of APDs. Postmarketing pharmacovigilance for
adverse effects of drugs has improved with the FDA Amendment
Act of 2007, which allowed for the creation of an active surveillance
system using electronic data from health care providers via the
Sentinel Initiative (FDA, 2011). Nonetheless, observational phar-
macoepidemiology studies examining APD-induced weight gain
suffer from several confounders (Ramaswamy et al., 2006). For
example, patients taking antipsychotics often have higher back-
ground rates of metabolic disorders, longitudinal follow-up to
detect metabolic abnormalities from chronic APD use is lim-
ited, the validity of using diagnosis codes may be questionable
(particularly for ascertaining obesity), there may be differential
disease surveillance rates, and use of over-the-counter weight loss
products may not be tracked. Data on family history, BMI status,
dietary intake, and level of physical activity (known risk factors for
metabolic abnormalities) are lacking in electronic claims data and
represent sources of unmeasured confounding. Electronic medical
records offer promise for studies of outcomes such as BMI, glucose,
and lipid profiles, but careful exploration of the completeness of
such data sources and the potential for confounding through infor-
mative absence of data (e.g., a higher likelihood of values being
recorded when overweight or other metabolic problems exist) is a
necessary initial step in such studies. Linking specific antipsychotic
exposure to weight gain is also challenging because of frequent
medication switching to optimize clinical response, as well as drug
selection bias, e.g., drugs with a greater propensity for weight gain
FIGURE 1 | Blood glucose and lipid monitoring in adult and pediatric
patients. In adult patients, monitoring did not significantly change after the
Dec. 2003 FDA warning. Monitoring is also low in pediatric patients after
the warning. Data from Morrato et al. (2010a,b).
may be used less often in patients who are already overweight.
Other psychotropic medications prescribed to patients with psy-
chosis, including antidepressants and mood stabilizers, can also
contribute to weight gain. These methodological challenges lead
to delays in drug causality determinations and result in delayed
changes in clinical practice and policy decisions. However, despite
these challenges, sufficient clinical and pharmacoepidemiologic
evidence has been generated over time to result in changes in
antipsychotic risk mitigation, including FDA labeling and ADA
guidelines that recommends baseline assessment and monitoring
of weight, hyperglycemia, and hyperlipidemia. A review of Med-
icaid datasets for 3-states suggests metabolic monitoring is not
routinely practiced and did not increase substantially in the year
following publication of ADA guidelines (Figure 1). Probably, the
most notable risk mitigation response has been a decline in OLZ
prescribing practices (Morrato et al., 2010a). Some states, such
as New York, have implemented quality improvement initiatives
aimed at reducing the use of antipsychotic medications associated
with higher risk of cardiometabolic disorders, such as OLZ, among
patients who have risk factors such as diabetes or pre-diabetes,
hypertension, hyperlipidemia, or cardiovascular disease (NYDH,
2010).
PEDIATRIC PATIENTS AND APDs
APD use in children (as young as 2 years of age) has increased
substantially over the past two decades (Olfson et al., 2006); in
particular, the off-label use of atypical antipsychotics in youth
has increased in the past decade (Zito et al., 2007; Crystal et al.,
2009). This increasing prescription of antipsychotic agents in chil-
dren occurs against the concerning backdrop of childhood obesity
in the general population; childhood onset of obesity is known
to be associated with increased obesity-related mortality risk in
early adulthood (Morrison et al., 2007). Most recent estimates
indicate that approximately 17% of the US population of youth
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ages 2–19 are considered obese, with an additional 15% of the
pediatric population at risk for developing obesity (Ogden et al.,
2010).
APDs are commonly used to treat bipolar disorder and early
onset schizophrenia in pediatric patients. In addition, APDs are
increasingly used to treat non-psychotic disorders, such as autism
spectrum disorders, oppositional personality disorder, Tourette
Syndrome, attention deficit hyperactivity disorder (ADHD), and
pervasive developmental disorder. APDs are also increasingly used
to treat oppositional, irritable, and aggressive behaviors across
diagnoses (Connor et al., 2006; Cooper et al., 2006), with lim-
ited evidence to support such off-label use. Children who are
publicly insured (e.g., Medicaid) are more commonly prescribed
psychotropic medications than privately insured children (Olfson
et al., 2002), and children in foster care who are publicly insured
represent the population of publicly insured children with the
greatest likelihood of being prescribed psychotropic medications
(Zito et al.,2008; Dosreis et al.,2011). Four percent of children aged
6–17 years of age enrolled in Medicaid were using antipsychotics
as of 2005, which is a 40–50% increase since 2001, and most of
these prescriptions (approximately 50%) were for the treatment of
ADHD or disruptive behavior disorders (Crystal et al., 2009). The
majority of children taking antipsychotics in this Medicaid cohort
were concomitantly taking other psychotropic drugs, whereas a
minority were treated with psychotherapy (Crystal et al., 2009).
Similar trends are seen in privately insured youth, although the
annual percentage of enrollees using APDs in this group was only
0.93% as of 2007 (Olfson et al., 2010). Several issues for concern
arise in this context, such as the low monitoring of metabolic risk
in both public- and privately insured populations (Haupt et al.,
2009; Morrato et al., 2010b), and additional metabolic risk con-
ferred by polypharmacy (McIntyre and Jerrell, 2008), contributed
to by poor access to high quality medical and mental health care
related to socio-economic disparity. This concurrent rise in APD
use in children along with the paucity of information on the safety
of such medications in children has led to a concerted effort among
researchers, clinicians, and policymakers to better understand this
issue.
Data from commercially insured (Haupt et al., 2009) and
Medicaid beneficiaries (Morrato et al., 2010b) indicate that most
persons using APDs do not receive glucose and dyslipidemia mon-
itoring (Figure 1), and that monitoring rates are lowest in the
youngest age groups. In a restrospective new-APD user cohort
study of 3-state Medicaid claims data from 2004 to 2006, rates
of fasting glucose and lipid testing were higher in non-diabetic
youth treated with APDs than in a control population of non-
diabetic youth (Morrato et al., 2010b). However, rates of incident
diabetes and hyperlipidemia during the study period, defined as
either a new diagnosis code or new prescription for anti-diabetes
or hyperlipidemia treatment, were on average higher in the APD-
treated group, with lower rates of anti-diabetes or hyperlipidemia
treatment noted in the APD-treated group.
In large observational databases like the multistate Medic-
aid analysis, youth taking antipsychotics compared to albuterol-
treated controls have higher rates of treatment-incident diagnosis
of diabetes and hyperlipidemia, without higher anti-diabetes or
hyperlipidemia treatment in the APD-treated population. This is
associated with the adverse medical outcomes that could be pre-
dicted; unfortunately at this stage and indication that it is not
properly treated. However, these observational studies are to a
large extent hypothesis-generating; clinical trials are needed to
test hypotheses and evaluate treatment-related metabolic changes
over time.
Similar or greater weight gain is seen across APDs in children
as in adults, although relative weight gain tends to be higher in
children (Shin et al., 2008), with some indication that perhaps ini-
tial antipsychotic exposure accounts for the higher weight gain
observed in younger patients (Table 1). The non-randomized
Second-Generation Antipsychotic Treatment Indications, Effec-
tiveness, and Tolerability in Youth (SATIETY) cohort study was
one of the first studies to specifically include antipsychotic-
naïve patients (Correll et al., 2009). The SATIETY study enrolled
antipsychotic-naïve patients aged 4–19 years (N = 272), with non-
randomized assignment to either aripiprazole (ARI), quetiapine
(QUET), risperidone (RISP),or olanzapine (OLZ). Although there
was potential for channeling bias at baseline in that many chil-
dren who were overweight or obese at baseline were assigned
to treatment with aripiprazole, weight gain was apparent in all
treatment groups after 12 weeks, including in the ARI treatment
group, which in previously exposed youth showed only minimal
weight gain (De Hert et al., 2011b). Olanzapine treatment was
associated with the highest weight gain (avg. 8.5 kg), with QUET,
RISP,and ARI producing somewhat less,but still substantial weight
gain (avg. 4.4 kg; Table 1). Cholesterol and triglyceride levels also
increased significantly in the OLZ and QUET groups, triglycerides
increased significantly with RISP, but ARI did not cause signif-
icant lipid increases despite significant weight gain. By contrast,
glucose, insulin, and insulin resistance increased significantly only
with OLZ, at least during the first 12 weeks of antipsychotic expo-
sure. The researchers suggested that the increased weight gain seen
in pediatric populations can be fully explained by a lack of prior
exposure to antipsychotics, because the degree of metabolic effects
was consistent with those seen in adult treatment-naïve patients
(Correll et al., 2011).
The recently completed NIH-funded MEAC (Metabolic Effects
of Antipsychotics in Children) study (MH72912, PI: Newcomer)
was the first to specifically evaluate gold-standard metabolic out-
comes in children and adolescents during an initial 12 weeks of
exposure to antipsychotics. Antipsychotic-naïve participants aged
6–18 with clinically significant aggression and irritability (score of
>18 on Aberrant Child Behavior Checklist Irritability Subscale)
in the setting of one or more DSM-IV diagnosis indicating a dis-
ruptive behavior disorder were enrolled. Participants (N = 144)
were randomized to specific antipsychotic treatments (RISP, OLZ,
ARI) following baseline assessments. Baseline and 12 week mea-
sures include body composition analysis with Dual Energy X-ray
Absorptiometry (DEXA) and abdominal MRI, as well as metabolic
testing including hyperinsulinemic euglycemic glucose clamps
with stable isotopomer tracing. Primary endpoints were change
in whole-body and abdominal adiposity, and whole-body and
tissue-specific insulin sensitivity. In the pooled group, combin-
ing all treatments, irritability scores were significantly improved.
However, during the 12 week trial, a mean DEXA-measured 2.4
(±3.1)% gain in total percent body fat was noted, corresponding
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to a 10 (±7) lb weight gain, and an associated mean decrease
in clamp-measured whole-body insulin sensitivity were observed.
Concerningly, greater weight gain was observed in the youngest
age group. Half of the participants had a primary diagnosis of
ADHD and were concurrently treated with a psychostimulant dur-
ing study participation. There was no clear relationship between
stimulant treatment and weight/adiposity change compared to
non-stimulant treated participants, reflecting results of a recent
study also suggested that stimulant medication may not mitigate
the metabolic effects of APDs in children (Penzner et al., 2009).
These results also support what was seen in large observational
database studies; the weight gain observed during antipsychotic
treatment is largely attributable to AP drug effect. Results from
long-term follow-up studies such as the Treatment of Early Onset
Schizophrenia Spectrum (TEOSS) study suggest that similar rates
of weight gain continue during extended AP treatment, with a
leveling off at 1 year after initial exposure (Findling et al., 2010),
and that molindone and RISP may exhibit more delayed-onset
weight gain than does OLZ. Overall, these studies highlight the
need for more frequent cardiometabolic monitoring in pediatric
patients after the initial 3 months of treatment and for addi-
tional research addressing the long-term cardiometabolic effects
of pediatric exposures.
GENETIC COMPONENTS UNDERLYING SUSCEPTIBILITY TO
APD-INDUCED METABOLIC EFFECTS
Given that the risk of metabolic syndrome risk associated with
APD use differs across ethnic groups, it can be inferred that genetic
factors may be playing a mediating role. In the general popula-
tion, rates of metabolic syndrome are lower in black and Hispanic
patients than in white patients, whereas rates of diabetes and CVD
are higher in black and Hispanic patients when compared to white
patients (Park et al., 2003). Ethnic differences in lipid profiles have
also been noted,and may lead to under-diagnosis of metabolic syn-
drome in blacks (Gaillard et al., 2009; Sumner, 2009). In addition,
the linear relationship between waist circumference and insulin
resistance seen in white patients does not hold true for black or
Hispanic patients (Nelson et al., 2008; Sumner et al., 2008). The
rates of death from CVD in Hispanic and black patients receiv-
ing clozapine (CLOZ) are 4.3 and 11.5 times the rates in whites,
respectively (Henderson et al., 2005).
Several genes have been identified that may mediate the effect
of APD-induced weight gain. A genome-wide association study
(GWAS) was conducted with the SATIETY cohort to determine
whether differential metabolic responses to antipsychotics are
associated with genetic markers. The analysis was conducted on
those exposed to QUET, RISP, and ARI and approximately 20
single nucleotide polymorphisms (SNPs) on Chr 18, near the
melanocortin four receptor gene (MC4R), were associated with
weight gain after antipsychotic exposure (Malhotra et al., 2012).
These results are consistent with other studies implicating rare
MC4R mutations in early onset obesity (Loos et al., 2008) and
more common variants downstream of MC4R that are associated
with obesity (Loos, 2011), and suggest that variants in this region
may confer susceptibility to weight gain while taking APDs. As
there was no randomized control group in this study to allow
for testing of an APD by genotype interaction, it is unclear if these
SNPs moderated the effects of APDs on weight gain or were merely
associated with weight gain among people taking APDs. In addi-
tion, SNPs in the serotonin 2c receptor (5HT2C) promoter region
(Reynolds et al., 2002) and Prohormone Convertase 1 (PCSK1)
gene were associated with APD related weight gain in the SATIETY
cohort and other obesity studies (Kilpelainen et al., 2009). PCSK1
metabolizes an MC4R ligand, suggesting that the genetic variants
found to date may converge on the proopiomelanocortin (POMC)
pathway (Lett et al., 2012). Ultimately, a clearer understanding of
the role of specific genes in treatment effect heterogeneity holds
much promise for the development of genetically informed, per-
sonalized treatment approaches, but further research is needed
before such approaches are practical on a routine basis (Lett et al.,
2012).
Several genetic factors may also mediate risk of developing
CVD when taking APDs. Associations have been detected between
metabolic syndrome risk (Ellingrod et al., 2008; van Winkel et al.,
2010) and variants in the methylenetetrahydrofolate reductase
(MTHFR) and catechol-o-methyl transferase (COMT ) genes was
detected in schizophrenia patients, which suggests that pertur-
bations in the Aldo Met cycle may be related to schizophrenia
and APD-induced metabolic effects. The Aldo Met cycle regulates
homocysteine levels, a marker associated with CVD risk; therefore
these gene variants may particularly affect CVD risk.
Other evidence suggests genes may interact with certain nutri-
ents to modify CVD risk when taking APDs. For example, n−3
fatty acid administration may offer a protective effect and inter-
act with gene variants (Amminger et al., 2010). When endothelial
functioning in schizophrenia patients was evaluated in relation to
n−3 fatty acid intake, endothelial function was lower in patients
than in healthy subjects, and the relationship between n−3 fatty
acid intake and endothelial function was modified by antipsychotic
exposure (Ellingrod et al., 2011). In addition, the COMT Val vari-
ant showed a significant association with physical activity in these
patients (Lott et al., 2012). Finally, preliminary evidence suggests
that folate supplementation, which may restore balance of the Aldo
Met cycle, improves endothelial function in schizophrenia patients
with metabolic syndrome (Ellingrod et al., 2012).
APD EFFECTS ONWEIGHT GAIN AND ADIPOSITY IN RELATION TO
THEIR ACUTE EFFECTS ON GLUCOSE REGULATION AND DIABETES RISK
Not surprisingly, increases in treatment-related adiposity pre-
dict insulin resistance in adults and children (Haupt et al., 2007;
Nicol and Newcomer, 2008; Newcomer et al., 2009). Consistent
with relative weight gain across the APDs, results from a recent
post-marketing survey across three U.S. insurer databases suggest
significant increased risk of diabetes for users of OLZ and CLOZ
but not ARI, ZIP, RISP, or QUET, when compared to users of
haloperidol (Yood et al., 2009). An important aspect of this study
was the inclusion of other non-psychiatric medications as covari-
ates (alpha and beta blockers, corticosteroids, oral contraceptives,
statins, etc.). Recent mechanistic studies described below suggest
that APD-associated insulin resistance can occur without weight
gain.
While the specific mechanism or mechanisms of APD-induced
weight gain are not fully understood, studies have shown that
affinity for the type 1 Histamine receptor explains the majority of
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the variance in weight gain between APDs (Kroeze et al., 2003),
with the proposed orexigenic mechanism being related to selec-
tive activation of hypothalamic AMP-kinase (Kim et al., 2007).
However, the promiscuity of the various APD drugs for interact-
ing with multiple receptor systems, many of which have direct
ties to regulating energy balance, further complicates understand-
ing the mechanism(s) by which APDs induce weight gain. APDs
are almost exclusively dopamine receptor 2 (DRD2) antagonists,
with the exception of partial agonists like ARI. All the second-
generation APDs also antagonize serotonin 2A and 2C receptors,
with variable antagonist activity at histamine, muscarinic and
α-adrenergic receptors and some agents are agonists or partial
agonists at the serotonin receptor 1A (e.g., ARI). Because of the
differential weight gain associated with different APDs, previ-
ous studies have suggested that APD binding to the serotonin 2c
receptor (5HT2c), histamine receptor (H1), and the dopamine D2
receptor (DRD2) plays an important role in APD-induced weight
gain (Nasrallah, 2008; Reynolds and Kirk, 2010).
Olanzapine and clozapine, which exhibit a particularly high
affinity for histamine and muscarinic receptors, are associated with
the most weight gain in patients and also cause increases in fasting
glucose, insulin, and triglycerides. The role of the neural control of
food intake and glucose homeostasis in this effect is currently being
explored. The role of the vagal nerve in insulin release during and
just after meals suggests that meal ingestion may uncover effects
that cannot be assessed in an intravenous glucose intervention
study. For example, a 12-day inpatient study of healthy individ-
uals given OLZ and ARI showed no increase in body weight or
food intake, but increased hunger (Teff, unpublished data). Fur-
thermore, no change in glucose production, small decreases in
glucose disposal, and a doubling of postprandial insulin response
were noted with OLZ, but not ARI. These results suggest that
a compensatory postprandial response of OLZ may explain the
insulin resistance seen in longer term studies. This study raises
the question of whether a sublingual route that avoids first-pass
hepatic metabolism may alleviate this effect, although the largest
randomized trial to date does not seem to support this assertion
(Karagianis et al., 2009). However, as noted above, the weight
gain potential of individual agents and not adiposity-independent
effects, is the primary factor associated with variation in insulin
sensitivity during treatment. It can be noted that there is some
evidence in animals for adiposity-independent effects on insulin
sensitivity (Houseknecht et al., 2007), but adiposity-independent
effects in humans have not been demonstrated. Moreover, these
results also raise the question of whether decreases in insulin
sensitivity precede or follow weight gain.
Results from animal models suggest OLZ may alter the adipose
tissue profile in addition to affecting insulin secretion. A canine
model showed no significant changes in body weight or caloric
intake, but a doubling of body fat, after 6 weeks of treatment
with OLZ but not RISP (Ader et al., 2005). This model suggests
OLZ promotes fat deposition associated with PPARγ expression,
hepatic insulin resistance, and impairment of the pancreatic beta
cell compensatory response. However, no impairment of glucose
tolerance was observed, and insulin levels were increased to a
greater extent than C-peptide, which is co-secreted with insulin.
These data suggest that OLZ treatment may alter both insulin
secretion and metabolic clearance of the hormone by the liver. In
a canine model of preexisting obesity via high-fat diet, OLZ was
associated with additional weight gain and adiposity compared
with ARI and placebo. The volume of visceral fat cells was dra-
matically increased in the OLZ-treated animals. Other studies have
suggested increased adipocyte inflammation in OLZ-treated ani-
mals (Victoriano et al., 2010) and activation of the TGFβ pathway
(Cohen et al., 2012). Importantly, while OLZ treatment impaired
insulin secretory function in vivo, perfusion of these pancreatic
islets in vitro demonstrated no significant defect of insulin release.
These data indicate that OLZ disturb pancreatic function not by
direct damage to pancreatic β-cells, but rather via interference
with signals to the pancreas, possibly secondary to an effect on the
central nervous system.
While development of a rodent model that reflects the mag-
nitude of weight gain seen in humans has been difficult due to
rapid metabolism in rodents (Kapur et al., 2000; Remington,2010),
research looking at acute effects have shown that hepatic glucose
production increases with CLOZ and OLZ, and insulin and C-
peptide responses to glucose load are reduced (Chintoh et al.,
2009). Subsequent studies using specific receptor blockers suggest
that D2/D3, M3, and 5HT2A antagonism may play a role in the
APD-induced acute glucose dysregulation (Hahn et al., 2011).
Although APDs increase body fat, evidence suggests they may
result in a paradoxical reduction of free fatty acid levels and
upregulation of fatty acid utilization. Metabolomic and meta-
bolic phenotyping after OLZ administration in rodents revealed
increased adiposity without a concomitant change in body weight,
decreased physical activity, an acute decrease in free fatty acids,
decreased lipolysis, and increased whole-body lipid oxidation
(Albaugh et al., 2011a, 2012). These studies are consistent with
three human studies that also showed acute decreases in free
fatty acids with APD treatment (Kaddurah-Daouk et al., 2007;
Vidarsdottir et al., 2010; Albaugh et al., 2011b). In addition, OLZ
administration is associated with a shift in relative fuel con-
sumption to fat oxidation, as measured by a rapid decline in
the respiratory exchange ratio (RER) during the dark cycle with-
out the normal rise in RER following meal ingestion (Albaugh
et al., 2012). A decline in RER would indicate greater consump-
tion of fat as fuel in comparison to carbohydrate or protein. It is
unclear how these metabolic effects may or may not contribute
to adiposity and insulin resistance associated with APD use, but
suggests that high free fatty acids and lipotoxicity are unlikely to
play a role.
The hypothesis that APDs may affect appetite regulation has
also been investigated. The Effect of Antipsychotics on Appetite
Regulation (ADAPT) study is an ongoing trial evaluating APD-
induced changes in appetite-regulating hormones in a treatment-
naïve population over 4 months (Brownley, 2011). Preliminary
data indicate no changes in pre- or post-prandial insulin or glucose
after an overnight fast resulting from APD use and APD reduced
caloric intake on average, despite some, though not all, individuals
gaining a significant amount of weight (Brownley, unpublished
data). An increase in hunger was reported in those who gained
weight, but a decrease was reported in those who lost weight. APD-
induced weight gain was associated with decreased ghrelin levels
and increased peptide tyrosine-tyrosine (PYY), and resting energy
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expenditure was decreased. The increases in PYY suggest compen-
sation in peripheral release in response to down-regulated central
PYY receptors and implicate perturbation of the reward system in
the antipsychotic-induced metabolic changes. Such implications
are supported by the results of Wang and Huang who demon-
strated decreases in central PYY binding densities in rat brain
after chronic administration of OLZ, but not haloperidol (Wang
and Huang, 2008).
Similar to the differences seen in human populations, OLZ
and CLOZ cause increased lipid accumulation in the nematode
C. elegans, whereas haloperidol and fluphenazine did not (Dwyer
et al., 2005). Consistent with the hypothesis of APD-induced
appetite regulation disturbances, foraging behavior in C. elegans
is increased following CLOZ and OLZ exposure and is associated
with insulin receptor-controlled activation of Akt and subsequent
FOXO (DAF-16) nuclear localization (Weeks et al., 2011).
BEHAVIORAL, DIETARY, AND PHARMACOLOGICAL INTERVENTIONS TO
MITIGATE APD-INDUCED METABOLIC SIDE EFFECTS
The differences in incidence of obesity and metabolic complica-
tions in patients taking APDs compared to the general population
may be in part due to lack of preventative care for metabolic
diseases in the psychiatric patient population (Newcomer and
Hennekens, 2007). Particularly low rates of treatment for hyper-
tension, dyslipidemia, and diabetes were evident in the patients
enrolled in the CATIE trial when compared to the general popu-
lation (Nasrallah et al., 2006). Furthermore, the Food and Drug
Administration (FDA) warnings for APDs have not produced sub-
stantial changes in practice, such as increased lipid and glucose
monitoring, in both publicly and privately insured populations of
patients (Haupt et al., 2009; Morrato et al., 2009, 2010a). The
gap in monitoring is particularly evident in pediatric patients
(Haupt et al., 2009). In one Medicaid study, glucose and lipid
testing among APD users varied significantly between states and
counties; patients with diagnosed cardiometabolic co-morbidity,
serious mental illness, persistent use of APDs, and with greater
frequency of non-psychiatric medical office visits were more likely
to be screened (Morrato et al., 2011). More effort is needed to
understand reasons for screening disparities in order to inform
risk management quality improvement interventions. For exam-
ple, recent studies have shown that rates of metabolic monitoring
have increased in some Medicaid populations (Moeller et al., 2011)
and significant improvements can be made in Community Mental
Health Centers by applying principles of diffusion of innovation
theory (Morrato et al., 2010b; Nicol et al., 2011).
The attitudes of psychiatric patients toward weight gain and
their desire to lose weight are consistent with those of the general
population (Strassnig et al., 2005; Ganguli and Strassnig, 2011).
The WAIST study introduced weight loss behavioral therapy in a
group setting in a schizophrenia patient population (Brar et al.,
2005). The therapy included self-monitoring actions such as daily
weighing, using a pedometer, using a food diary, and the addi-
tional incentive of a monetary reward (Brar et al., 2005). Therapy
also included making eating a specific activity, slowing the rate of
eating, and getting over the inhibition of wasting food. Physical
activity was increased mainly by using a walking in place video pro-
gram. As an active control, social skills training was implemented
as an alternative behavioral therapy. After 14 weeks, weight loss was
significantly greater in the behavioral therapy group than in the
social skills training and usual care groups, with one-quarter of the
patients losing more than 5% of their body weight at the endpoint
(Brar et al., 2005). Currently, research is focused on determin-
ing whether behavioral interventions are associated with increased
maintenance of weight loss after 2 years in those patients who did
lose weight.
Several pharmacologic interventions have been tested in
patients taking APDs to counteract the weight gain and meta-
bolic complications associated with these drugs. Metformin, and
topiramate have demonstrated efficacy in weight loss trials in
patients receiving APD treatment with an average weight loss
of approximately 2–3 kg after 8–12 weeks of treatment; fenflu-
ramine, sibutramine, and reboxetine, show similar effects but
have been removed from the market due to side effect concerns
(Maayan et al., 2010). Metformin not only reduces weight, but
also improves fasting insulin and insulin resistance in first-episode
patients more efficiently than does a life-style intervention alone,
but is even more effective when combined with a life-style inter-
vention (Wu et al., 2008). Slow-release metformin induces weight
loss even after long-term CLOZ treatment (Carrizo et al., 2009).
Interestingly, metformin may act through improving leptin sen-
sitivity, and certain mutations in leptin may prevent metformin
action (Fernandez et al., 2010). Topiramate improves triglycerides,
glucose, leptin, cholesterol, and blood pressure in OLZ-treated
patients in addition to promoting weight loss (Narula et al., 2010).
Notably, however, all drug and behavioral interventions produced
modest weight loss. Improved interventions are needed, and the
appropriateness of bariatric surgery in this population could be
explored.
Some evidence suggests that using pharmacologic agents for
weight loss may interfere with the therapeutic effects of antipsy-
chotic treatment (Baptista et al., 2008). In one study, the treatment
algorithm producing the most weight loss via metformin admin-
istration suggested reduced improvement in depression (Hoff-
mann et al., 2011). In addition, topiramate is associated with a
worsening of cognitive functions, and amantadine may worsen
psychosis (Baptista et al., 2008). Thus, patients taking amanta-
dine and topiramate to reduce weight gain should be monitored
carefully.
Switching of antipsychotic medications has been investigated
for effects on weight gain and metabolic complications. Overall,
switching from RISP or OLZ (medium and high weight gain drugs)
to ZIP or ARI (lower weight gain drugs) does produce weight loss
and modestly improves triglycerides and cholesterol (Mukundan
et al., 2010; Stroup et al., 2011). Unfortunately, at least for a sub-
group of patients, drugs that cause less weight gain may not be as
effective in treating psychosis as are those that cause more weight
gain, although the CATIE data shows a very modest correlation
between clinical improvement and increase in BMI (Hermes et al.,
2011). In the CATIE trial, patients who stayed on the same medica-
tion and avoided switching were more likely to stay in treatment,
and those taking an effective medication were more likely to regress
if they switched (Essock et al., 2006). In another trial, switching
from the higher risk OLZ to lower risk RISP or QUET did not result
in increased psychiatric risk, and patients who switched gained
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less weight than did those who stayed on OLZ (Rosenheck et al.,
2009). Regarding recommendations for clinicians, a meta-analysis
of APD clinical trials suggests that CLOZ, OLZ, and RISP appear
to most consistently show superior efficacy (Leucht et al., 2009a,b;
Glick et al., 2011); for first-episode schizophrenic patients, how-
ever, who are both most sensitive to APD adverse effects and
have higher therapeutic response rates, antipsychotics showing
less weight gain liability should be prescribed first and only those
patients who do not respond should be switched to potentially
more effective, higher weight gain treatments (Buchanan et al.,
2010; Agid et al., 2011).
Several pretreatment or early treatment characteristics have
been associated with APD outcomes and may be useful for pre-
dicting APD response. Although the initial analysis of the CATIE
trial dataset suggested that patients with metabolic syndrome did
not have lower cognitive performance than did patients without
metabolic syndrome (Meyer et al., 2005), a recent re-analysis sug-
gests a significant, although small and clinically irrelevant, negative
association between BMI and the Positive and Negative Symp-
tom Scale (PANSS) total score, and this association did not differ
across antipsychotic medications (Hermes et al., 2011). However,
findings regarding associations of weight gain with improvement
in symptoms after antipsychotic treatment are varied and con-
troversial (Correll et al., 2011; De Hert et al., 2011a) and Kelly,
unpublished data).
CONCLUDING REMARKS
In conclusion, the conference presentations highlighted progress
in many novel areas of APD-induced metabolic dysfunc-
tion research. Recent results from pharmacogenetic studies
are suggestive of mechanistic pathways, yet methodological
considerations will be important in designing future studies to
tease apart APD-gene relationships. More problematic weight gain
trajectories are evident in the growing number of pediatric patients
being prescribed APDs, although long-term studies are needed to
determine if metabolic consequences in pediatric patients lead
to greater or earlier disease risk in later life since we have much
less information on long-term effects than short-term effects, and
long-term effects are very difficult to track with existing treatment
designs. This dilemma arguably demonstrates the importance of
a conservative, cautious approach in dosing (start low, go slow)
and careful metabolic monitoring of patients. Trials of discon-
tinuation after long-term use might also be useful. Novel studies
investigating acute effects of APD exposure on metabolic dysfunc-
tion in animal and human studies suggest immediate effects on
glucose regulation may play a role in APD-induced metabolic
dysfunction. Lastly, combined behavioral, dietary, and pharma-
cological interventions are showing some promise in mitigating
APD-induced metabolic side effects, but novel agents are needed
that can more completely prevent or reverse ADP related weight
gain and metabolic abnormalities.
Future research is needed to determine mechanistically how
APDs lead to metabolic disturbances and weight gain in order to
facilitate development of effective combination therapies to negate
these effects or to develop new drugs that do not induce weight
gain. In addition, future work should also determine what factors
predict weight gain so that clinical guidelines for prescribing APDs
and managing weight gain and its consequences can be improved.
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